Clinical study on the efficacy and safety of ultra-picosecond laser combined with local injection of PRP in the treatment of periorbital hyperpigmentation (POH)

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500107373

Enrollment

Unknown

Registered

2025-08-11

Start date

2025-08-11

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

periorbital hyperpigmentation

Interventions

Experimental group:Ultra-picosecond laser and PRP injection treatments

Control group:Picosecond laser treatment

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with pigmented dark circles or mixed dark circles with pigmented types. "Pigment-based" means that the periorbital pigmentation area is predominantly brown, and pink or purple is not obvious. Study participants took cloud mirror photographs to observe the degree of pigmentation before enrollment. 2. Fitzpatrick's skin type is type II., type III. or type IV. 3. Age over 18 years old, gender is not limited. 4. Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Any signs of eye infection or inflammation. 2. Use of photosensitizing drugs or periocular injections and surgery in the past 12 months. 3. Platelet count < 150×10^9/L. 4. Sun exposure cannot be avoided before and within 4 weeks after treatment. 5. Pregnant and lactating women. 6. Suffering from other skin diseases, hematological diseases, serious chronic diseases, such as chronic renal failure, liver insufficiency/hepatitis, cardiovascular disease, diabetes, thyroid disease, cancer, chronic inflammatory diseases (such as lupus erythematosus, scleroderma, dermatomyositis, vasculitis, inflammatory bowel disease, rheumatoid arthritis, etc.). 7. History of keloid formation. 8. Take non-steroidal anti-inflammatory drugs, steroid hormones, and anticoagulants. 9. Drugs that affect pigment metabolism, such as hydroquinone, tretinoin, etc. are being used. 10. Patients with unrealistic expectations. For example, the periorbital pigmentation is expected to completely subside after 3 treatments, or there is no periorbital congestion during treatment. 11. Those who are allergic to thrombin, calcium gluconate and lidocaine.

Design outcomes

Primary

Measure	Time frame
VAS score;	—

Secondary

Measure	Time frame
Investigator Global Assessment;Degree of suborbital pigmentation;Overall satisfaction score;VAS pain score;tear trough rating scale;	—

Countries

China

Contacts

Public ContactHan Ma

Sun Yat sen University Affiliated Fifth Hospital

mhan@mail.sysu.edu.cn+86 131 2824 7946

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026